Minimal Clinically Important Differences for the Experiences of Daily Living Parts of Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale

被引:72
作者
Horvath, Krisztina [1 ]
Aschermann, Zsuzsanna [1 ,2 ]
Kovacs, Marton [1 ,2 ]
Makkos, Attila [1 ,2 ]
Harmat, Mark [1 ,2 ]
Janszky, Jozsef [2 ,3 ]
Komoly, Samuel [2 ]
Karadi, Kazmer [1 ,4 ]
Kovacs, Norbert [2 ,3 ]
机构
[1] Univ Pecs, Doctoral Sch Clin Neurosci, Pecs, Hungary
[2] Univ Pecs, Dept Neurol, Ret Utca 2, H-7623 Pecs, Hungary
[3] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary
[4] Univ Pecs, Dept Behav Sci, Pecs, Hungary
关键词
minimal clinically important changes; minimal but clinically relevant differences; receiver operating; characteristic curve; UPDRS; patient reported outcomes; DEEP BRAIN-STIMULATION; IMPACT;
D O I
10.1002/mds.26960
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The minimal clinically important difference is the smallest change of scores clinically meaningful to patients. Objectives: We aimed to calculate these threshold values in association with the International Parkinson and Movement Disorder Society UPDRS (MDS-UPDRS) Parts I and II and to evaluate the feasibility of the composite score of Part I and II (MDS-UPDRS I+II) as an outcome. Methods: Nine hundred eighty-five paired investigations of 365 patients were reviewed, implementing three different techniques simultaneously. Results: Based on the ordinal regression modeling, the MDS-UPDRS I+II score is an applicable outcome measure. Any improvement greater than 2.64 points or any worsening more than 2.45 points on MDS-UPDRS Part I represent a minimal, yet clinically meaningful change. In reference to Part II, the smallest changes considered clinically relevant were 3.05 and 2.51 points for improvement and deterioration, respectively. The thresholds for MDS-UPDRS I+II were 5.73 points for improvement and 4.70 points for worsening. Conclusions: Our minimal clinically important difference thresholds can be utilized in clinical practice in judging clinical relevance. (C) 2017 International Parkinson and Movement Disorder Society
引用
收藏
页码:789 / 793
页数:6
相关论文
共 27 条
  • [1] [Anonymous], 1988, Statistical power analysis for the behavioral sciences
  • [2] Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease
    Aviles-Olmos, Iciar
    Dickson, John
    Kefalopoulou, Zinovia
    Djamshidian, Atbin
    Kahan, Joshua
    Ell, Peter
    Whitton, Peter
    Wyse, Richard
    Isaacs, Tom
    Lees, Andrew
    Limousin, Patricia
    Foltynie, Thomas
    [J]. JOURNAL OF PARKINSONS DISEASE, 2014, 4 (03) : 337 - 344
  • [3] Scales for Assessing Nonmotor Symptom Severity Changes in Parkinson's Disease Patients With Symptom Fluctuations
    Buck, Philip O.
    Trautman, Holly
    Clark, Jamie
    [J]. INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2010, 120 (08) : 523 - 530
  • [4] The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease
    Chou, Kelvin L.
    Taylor, Jennifer L.
    Patil, Parag G.
    [J]. PARKINSONISM & RELATED DISORDERS, 2013, 19 (11) : 966 - 969
  • [5] Bilateral Subthalamic Stimulation can Improve Sleep Quality in Parkinson's Disease
    Deli, Gabriella
    Aschermann, Zsuzsanna
    Acs, Peter
    Bosnyak, Edit
    Janszky, Jozsef
    Faludi, Bela
    Makkos, Attila
    Kovacs, Marton
    Komoly, Samuel
    Balas, Istvan
    Doczi, Tamas
    Kovacs, Norbert
    [J]. JOURNAL OF PARKINSONS DISEASE, 2015, 5 (02) : 361 - 368
  • [6] Socioeconomic Status May Impact Functional Outcome of Deep Brain Stimulation Surgery in Parkinson's Disease
    Genc, Gencer
    Abboud, Hesham
    Oravivattanakul, Srivadee
    Alsallom, Faisal
    Thompson, Nicolas R.
    Cooper, Scott
    Gostkowski, Michal
    Machado, Andre
    Fernandez, Hubert H.
    [J]. NEUROMODULATION, 2016, 19 (01): : 25 - 29
  • [7] Movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations
    Goetz, CG
    Poewe, W
    Rascol, O
    Sampaio, C
    Stebbins, GT
    Counsell, C
    Giladi, N
    Holloway, RG
    Moore, CG
    Wenning, GK
    Yahr, MD
    Seidl, L
    [J]. MOVEMENT DISORDERS, 2004, 19 (09) : 1020 - 1028
  • [8] Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
    Goetz, Christopher G.
    Tilley, Barbara C.
    Shaftman, Stephanie R.
    Stebbins, Glenn T.
    Fahn, Stanley
    Martinez-Martin, Pablo
    Poewe, Werner
    Sampaio, Cristina
    Stern, Matthew B.
    Dodel, Richard
    Dubois, Bruno
    Holloway, Robert
    Jankovic, Joseph
    Kulisevsky, Jaime
    Lang, Anthony E.
    Lees, Andrew
    Leurgans, Sue
    LeWitt, Peter A.
    Nyenhuis, David
    Olanow, C. Warren
    Rascol, Olivier
    Schrag, Anette
    Teresi, Jeanne A.
    van Hilten, Jacobus J.
    LaPelle, Nancy
    [J]. MOVEMENT DISORDERS, 2008, 23 (15) : 2129 - 2170
  • [9] Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
    Hauser, Robert A.
    Gordon, Mark Forrest
    Mizuno, Yoshikuni
    Poewe, Werner
    Barone, Paolo
    Schapira, Anthony H.
    Rascol, Olivier
    Debieuvre, Catherine
    Fraessdorf, Andmandy
    [J]. PARKINSONS DISEASE, 2014, 2014
  • [10] Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease
    Hauser, Robert A.
    Auinger, Peggy
    [J]. MOVEMENT DISORDERS, 2011, 26 (05) : 813 - 818